As a medical cardiologist treating patients for secondary prevention of ASCVD, can you share with us the outcomes and disease course of patients you have managed with PCSK9 inhibitors? Has the cost reductions affected your appetite for these agents?

As a medical cardiologist treating patients for secondary prevention of ASCVD, can you share with us the outcomes and disease course of patients you have managed with PCSK9 inhibitors? Has the cost reductions affected your appetite for these agents?

As a medical cardiologist treating patients for secondary prevention of ASCVD, can you share with us the outcomes and disease course of patients you have managed with PCSK9 inhibitors? Has the cost reductions affected your appetite for these agents?


Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical Cardiology, Interventional Cardiology, Lipid Medicine, Atherosclerosis and Diabetes Specialist's Perspective

Presenter

R. Scott Wright, MD

R. Scott Wright, MD

Professor of Medicine Department of Cardiovascular Medicine Cardiovascular Division Mayo Clinic